ERBB2 and neoplasm: Immune cell‐redirecting, anti‐CD3/anti‐TAA‐based cell‐bridging bsAbs on the other hand utilize not only tissue‐specific tumor antigens (PSMA, GPC3, etc.)but also fewer specific antigens (HER2, EpCAM, CEA, etc.).